vs

Side-by-side financial comparison of CARTERS INC (CRI) and ResMed (RMD). Click either name above to swap in a different company.

ResMed is the larger business by last-quarter revenue ($1.4B vs $757.8M, roughly 1.9× CARTERS INC). ResMed runs the higher net margin — 27.6% vs 1.5%, a 26.1% gap on every dollar of revenue. On growth, ResMed posted the faster year-over-year revenue change (11.0% vs -0.1%).

Carter's, Inc. is a major American designer and marketer of children's apparel. It was founded in 1865 by William Carter.

ResMed Inc. is a medical equipment company based in San Diego, California, and founded in Australia. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Resmed produced hundreds of thousands of ventilators and bilevel devices to help treat the respiratory symptoms of patients with COVID-19.

CRI vs RMD — Head-to-Head

Bigger by revenue
RMD
RMD
1.9× larger
RMD
$1.4B
$757.8M
CRI
Growing faster (revenue YoY)
RMD
RMD
+11.1% gap
RMD
11.0%
-0.1%
CRI
Higher net margin
RMD
RMD
26.1% more per $
RMD
27.6%
1.5%
CRI

Income Statement — Q3 FY2026 vs Q4 FY2026

Metric
CRI
CRI
RMD
RMD
Revenue
$757.8M
$1.4B
Net Profit
$11.6M
$392.6M
Gross Margin
45.1%
61.8%
Operating Margin
3.8%
34.6%
Net Margin
1.5%
27.6%
Revenue YoY
-0.1%
11.0%
Net Profit YoY
-80.1%
13.9%
EPS (diluted)
$0.32
$2.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRI
CRI
RMD
RMD
Q2 26
$1.4B
Q1 26
$1.4B
Q4 25
$1.4B
Q3 25
$757.8M
$1.3B
Q2 25
$585.3M
$1.3B
Q1 25
$629.8M
$1.3B
Q4 24
$1.3B
Q3 24
$1.2B
Net Profit
CRI
CRI
RMD
RMD
Q2 26
$392.6M
Q1 26
$398.7M
Q4 25
$392.6M
Q3 25
$11.6M
$348.5M
Q2 25
$446.0K
$379.7M
Q1 25
$15.5M
$365.0M
Q4 24
$344.6M
Q3 24
$311.4M
Gross Margin
CRI
CRI
RMD
RMD
Q2 26
61.8%
Q1 26
62.2%
Q4 25
61.8%
Q3 25
45.1%
61.5%
Q2 25
48.1%
60.8%
Q1 25
46.2%
59.3%
Q4 24
58.6%
Q3 24
58.6%
Operating Margin
CRI
CRI
RMD
RMD
Q2 26
34.6%
Q1 26
34.9%
Q4 25
34.6%
Q3 25
3.8%
33.4%
Q2 25
0.7%
33.7%
Q1 25
4.1%
33.0%
Q4 24
32.5%
Q3 24
31.6%
Net Margin
CRI
CRI
RMD
RMD
Q2 26
27.6%
Q1 26
27.9%
Q4 25
27.6%
Q3 25
1.5%
26.1%
Q2 25
0.1%
28.2%
Q1 25
2.5%
28.3%
Q4 24
26.9%
Q3 24
25.4%
EPS (diluted)
CRI
CRI
RMD
RMD
Q2 26
$2.68
Q1 26
$2.74
Q4 25
$2.68
Q3 25
$0.32
$2.37
Q2 25
$0.01
$2.58
Q1 25
$0.43
$2.48
Q4 24
$2.34
Q3 24
$2.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRI
CRI
RMD
RMD
Cash + ST InvestmentsLiquidity on hand
$184.2M
$1.4B
Total DebtLower is stronger
$663.8M
Stockholders' EquityBook value
$864.6M
$6.3B
Total Assets
$2.5B
$8.5B
Debt / EquityLower = less leverage
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRI
CRI
RMD
RMD
Q2 26
$1.4B
Q1 26
$1.7B
Q4 25
$1.4B
Q3 25
$184.2M
$1.4B
Q2 25
$338.2M
$1.2B
Q1 25
$320.8M
$932.7M
Q4 24
$521.9M
Q3 24
$426.4M
Total Debt
CRI
CRI
RMD
RMD
Q2 26
$663.8M
Q1 26
$664.1M
Q4 25
$403.9M
Q3 25
$408.7M
Q2 25
$658.4M
Q1 25
$663.1M
Q4 24
$662.9M
Q3 24
$667.6M
Stockholders' Equity
CRI
CRI
RMD
RMD
Q2 26
$6.3B
Q1 26
$6.5B
Q4 25
$6.3B
Q3 25
$864.6M
$6.1B
Q2 25
$853.9M
$6.0B
Q1 25
$847.2M
$5.5B
Q4 24
$5.3B
Q3 24
$5.2B
Total Assets
CRI
CRI
RMD
RMD
Q2 26
$8.5B
Q1 26
$8.8B
Q4 25
$8.5B
Q3 25
$2.5B
$8.3B
Q2 25
$2.5B
$8.2B
Q1 25
$2.3B
$7.6B
Q4 24
$7.1B
Q3 24
$7.2B
Debt / Equity
CRI
CRI
RMD
RMD
Q2 26
0.11×
Q1 26
0.10×
Q4 25
0.06×
Q3 25
0.07×
Q2 25
0.11×
Q1 25
0.12×
Q4 24
0.13×
Q3 24
0.13×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRI
CRI
RMD
RMD
Operating Cash FlowLast quarter
$-128.0M
Free Cash FlowOCF − Capex
$-144.1M
FCF MarginFCF / Revenue
-19.0%
Capex IntensityCapex / Revenue
2.1%
Cash ConversionOCF / Net Profit
-11.04×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRI
CRI
RMD
RMD
Q2 26
Q1 26
Q4 25
$339.7M
Q3 25
$-128.0M
$457.3M
Q2 25
$40.3M
$538.8M
Q1 25
$-48.6M
$578.7M
Q4 24
$308.6M
Q3 24
$325.5M
Free Cash Flow
CRI
CRI
RMD
RMD
Q2 26
Q1 26
Q4 25
$311.2M
Q3 25
$-144.1M
$414.4M
Q2 25
$24.1M
$508.2M
Q1 25
$-59.0M
$557.9M
Q4 24
$288.0M
Q3 24
$307.7M
FCF Margin
CRI
CRI
RMD
RMD
Q2 26
Q1 26
Q4 25
21.9%
Q3 25
-19.0%
31.0%
Q2 25
4.1%
37.7%
Q1 25
-9.4%
43.2%
Q4 24
22.5%
Q3 24
25.1%
Capex Intensity
CRI
CRI
RMD
RMD
Q2 26
Q1 26
Q4 25
2.0%
Q3 25
2.1%
3.2%
Q2 25
2.8%
2.3%
Q1 25
1.6%
1.6%
Q4 24
1.6%
Q3 24
1.5%
Cash Conversion
CRI
CRI
RMD
RMD
Q2 26
Q1 26
Q4 25
0.87×
Q3 25
-11.04×
1.31×
Q2 25
90.37×
1.42×
Q1 25
-3.13×
1.59×
Q4 24
0.90×
Q3 24
1.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CRI
CRI

Sales Channel Directly To Consumer$362.3M48%
Sales Channel Through Intermediary$283.8M37%
Other$110.4M15%
Gift Cards$1.3M0%

RMD
RMD

Segment breakdown not available.

Related Comparisons